<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435744</url>
  </required_header>
  <id_info>
    <org_study_id>PILL-DepSTAT-001</org_study_id>
    <nct_id>NCT03435744</nct_id>
  </id_info>
  <brief_title>Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.</brief_title>
  <acronym>DepSTAT</acronym>
  <official_title>A Multicentre 12-week Randomised, Double Blind, Placebo Controlled Trial of Simvastatin as Augmentation Treatment for Treatment-resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double blind, randomized placebo controlled trial we aim to determine the efficacy of&#xD;
      simvastatin as an add-on treatment for treatment resistant depression. We will recruit 150&#xD;
      people with treatment-resistant depression with the aim of determining whether the addition&#xD;
      of simvastatin (20mg daily) to treatment as usual (TAU) for 12 weeks leads to an improvement&#xD;
      in depressive symptom compared with placebo added to TAU.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1-Simvastatin plus TAU, 2- Placebo plus TAU</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind plcaebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery Asberg, 1979)</measure>
    <time_frame>Week-2, Week-4, Week-8 and Week-12</time_frame>
    <description>The MADRS will be used as primary outcome measure in estimating depression severity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Simvastatin with TAU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Simvastatin 20 mg added to TAU for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet with TAU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo added to TAU for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 20 mg</intervention_name>
    <description>Simvastatin 20 mg added to TAU for 3 months.</description>
    <arm_group_label>Simvastatin with TAU</arm_group_label>
    <other_name>Statins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Matched placebo added to TAU for 3 months</description>
    <arm_group_label>Placebo Oral Tablet with TAU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-5 current major depressive episode&#xD;
&#xD;
          -  Must currently be on an antidepressant and must have had a non-response to &gt;2 oral&#xD;
             antidepressant treatments in the current episode (including the one they are currently&#xD;
             taking).&#xD;
&#xD;
          -  Capacity to give informed consent&#xD;
&#xD;
          -  Willing to use adequate contraception&#xD;
&#xD;
          -  Give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary psychotic or bipolar disorder&#xD;
&#xD;
          -  History of intolerance to statins or presence of any contraindication to statins&#xD;
&#xD;
          -  Presence of any serious medical condition or neurological problem&#xD;
&#xD;
          -  Presence of autoimmune or inflammatory disorder&#xD;
&#xD;
          -  Alcohol or drug dependence&#xD;
&#xD;
          -  Active suicidal ideation&#xD;
&#xD;
          -  Pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Civil Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civil Hospital</name>
      <address>
        <city>Karachi</city>
        <zip>75500</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbasi Shaheed Hospital</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Professional Psychology</name>
      <address>
        <city>Rawalpindi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

